down arrow

Jafron Biomedical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100002995
CNY
20.15
-1.81 (-8.24%)

Dec 05

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Jafron Biomedical Co., Ltd.
Why is Jafron Biomedical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 7.08% and Operating profit at 1.35% over the last 5 years
2
With a fall in Net Sales of -22.06%, the company declared Very Negative results in Mar 25
  • The company has declared negative results in Mar 25 after 4 consecutive negative quarters
  • NET SALES(Q) At CNY 538.66 MM has Fallen at -26.48%
  • OPERATING CASH FLOW(Y) Lowest at CNY 853.12 MM
  • PRE-TAX PROFIT(Q) Fallen at -37.36%
3
With ROE of 20.51%, it has a expensive valuation with a 3.63 Price to Book Value
  • Over the past year, while the stock has generated a return of -38.19%, its profits have fallen by -8.8%
  • At the current price, the company has a high dividend yield of 5.7
4
Below par performance in long term as well as near term
  • Along with generating -38.19% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Jafron Biomedical Co., Ltd. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
Jafron Biomedical Co., Ltd.
-100.0%
-0.81
29.64%
China Shanghai Composite
15.19%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
7.08%
EBIT Growth (5y)
1.35%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.45
Tax Ratio
19.47%
Dividend Payout Ratio
74.38%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
47.77%
ROE (avg)
24.21%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
3.63
EV to EBIT
13.09
EV to EBITDA
11.08
EV to Capital Employed
4.32
EV to Sales
4.69
PEG Ratio
NA
Dividend Yield
5.70%
ROCE (Latest)
33.00%
ROE (Latest)
20.51%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -6.05% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 26.32%

-11What is not working for the Company
NET SALES(Q)

At CNY 538.66 MM has Fallen at -26.48%

OPERATING CASH FLOW(Y)

Lowest at CNY 853.12 MM

PRE-TAX PROFIT(Q)

Fallen at -37.36%

NET PROFIT(Q)

Fallen at -37.28%

Here's what is working for Jafron Biomedical Co., Ltd.
Debtors Turnover Ratio
Highest at 26.32%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -6.05% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Jafron Biomedical Co., Ltd.
Net Sales
At CNY 538.66 MM has Fallen at -26.48%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (CNY MM)

Operating Cash Flow
Lowest at CNY 853.12 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Pre-Tax Profit
Fallen at -37.36%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit
Fallen at -37.28%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is negative

Net Profit (CNY MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."